“HOT” stock: Mineral Resources (MIN)
In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says he’s seeing positive signs for Mineral Resources (MIN).
Investment analysis, share recommendations, and market insights.
In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says he’s seeing positive signs for Mineral Resources (MIN).
The companies in question are Worley (WOR), Qube Holdings (QUB), Sonic Healthcare, Ampol, Magnis Energy Technologies, Helloworld Travel, Calix, and Iluka Resources. Let’s go through each one of these.
While our model portfolios lost ground with the share market pullback in April, they’re still outperforming the benchmark index. In this article, I look at how they have performed so far this year. To do so, let’s start by examining how the overall market has fared.
For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans explains why he considers Amcor (AMC) an an ADD to an investor’s portfolio.
Australia has large reserves of many critical minerals. Last year, high-purity alumina (HPA) was officially added to our critical minerals list. These minerals are used in high-technology items with rising consumer demand, particularly in China, North America, and Europe. Here are three companies in the HPA market I think are worth a closer look – though this kind of investment must be considered speculative.
ETFs are useful to keep cash available to pounce on stock bargains in coming months. Here are two for you to consider.
In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, explains why he sees Macquarie Group (MQG) as a buying opportunity.
We’re currently in a pullback that could evolve into a 10% plus correction. However, that only provides a buying opportunity for the long-term investor.
In this article, I’ll look at the three changes for this year, and what we know about the new super tax on balances over $3 million (and if you’re impacted, what you may want to do).
For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans explains why Morgans views Resmed (RMD) as an ADD to an investor’s portfolio.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.